Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 in Chronic Hepatitis B
NCT04133259Phase 2Unknown
- Sponsor
- Henlix Biotech
- Start
- Dec 2019
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in Chronic Hepatitis B (CHB), sponsored by Henlix Biotech. Status: unknown.
02
Drugs
serplulimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04133259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133259.